Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care

An intratumoral drug-releasing microdevice implanted in glioma patients can measure the drug’s antitumor effects and could potentially help guide treatment, early data suggest. (Brigham and Women’s Hospital, Science Translational Medicine)

Mississippi’s cervical cancer death rate may indicate broader healthcare issues. (KFF Health News)

Researchers have developed a novel test that is sensitive for detecting cervical adenocarcinoma — a hard-to-find cancer that accounts for up to 25% of cervical cancer cases. (Montefiore Einstein Cancer Center)

Seagen and Genmab announced that the phase III confirmatory innovaTV 301 trial of tisotumab vedotin (Tivdak) met its primary endpoint by improving overall survival as second-line therapy versus chemotherapy alone for patients with recurrent or metastatic cervical cancer.

Endometrial cancer risk was lower for women with late menarche, early menopause, or a higher number of deliveries, a study in Asian women found. (JAMA Network Open)

Durvalumab (Imfinzi) added to curative radiotherapy showed promise in a small single-arm trial of locally advanced unresectable PD-L1 positive non-small cell lung cancer (NSCLC). (JAMA Oncology)

A diet and exercise intervention was associated with a higher rate of pathological complete response in patients with breast cancer undergoing neoadjuvant chemotherapy. (Journal of Clinical Oncology)

A commercially available artificial intelligence algorithm was as effective as human readers in detecting breast cancer. (Radiology)

One in eight cancer patients with no history of depression developed new-onset depression during the early part of the COVID-19 pandemic, while half of those with a history had a recurrence. (Cancer Management and Research)

Bristol Myers Squibb has been accused in a lawsuit of using illegal tactics to maintain its monopoly on pomalidomide (Pomalyst) — used to treat multiple myeloma — when it should have faced generic competition. (Reuters)

Patients with acute myeloid leukemia who received vitamin C and D supplements while undergoing intensive chemotherapy had lower rates of complications — such as infections, bleeding, and inflammation — but experienced no overall survival benefit. (Blood Advances)

State public assistance spending was tied to overall survival for socioeconomically disadvantaged people with cancer. (JAMA Network Open)

Janssen announced that the phase III MARIPOSA-2 study evaluating amivantamab (Rybrevant) plus chemotherapy with or without the investigational EGFR inhibitor lazertinib met its primary endpoint by extending PFS when compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC.

A study found that most non-English speakers who call a hospital general information line are unable to get information on the steps they must take to access cancer care. (Journal of the National Comprehensive Cancer Network).

Please enable JavaScript to view the

comments powered by Disqus.